Dec 22, 2011

New Phase III Cancer Clinical Trials - December 2011

     Our search, carried out on December 22, showed 22 new phase III trials registered in the last 30 days.  We will highlight two that explore immunotherapy in two very different contexts.  
     The first trial compares the use of the patient's own stimulated killer cells (a part of one's natural immune system) to the use of chemotherapy in advanced lung cancer.  The study is being carried out in China, so it is likely inaccessible to most US cancer patients, but it is a good example of how immunotherapy continues to be a major direction for cancer clinical trials.  
     The second trial tests a vaccine product called NeuVax (TM) to determine if the vaccine can prevent the relapse of breast cancer.  Patients who have early stage node positive breast cancer that has low or intermediate expression of the HER2 protein are eligible.  Experimental treatment follows the completion of standard treatments such as surgery, radiation, and chemotherapy.
     You can click on the hyperlinks above to see each individual trial or click here to learn more about both of them:
New immunotherapy trials Dec 2011 (click here - link expires March 21, 2012)
     To see all 22 new phase III trials registered in the last 30 days, click here:
All new phase III cancer trials Dec 2011 (click here - link expires March 21, 2012)

Dec 21, 2011

Cancer Clinical Trials - testing, feedback, and see you in 2012

We are still in the development stage of this blog.  We welcome your comments about the look and feel and design of the blog.  Expect the blog to "go live" with regular additions of new content in early 2012.

Dec 18, 2011

Welcome to the cancer clinical trials blog!

Simple, accessible, trustworthy, and practical information about cancer clinical trials and the experimental therapies they offer is what we aim to bring you here.  We welcome your comments, suggestions, and questions.  This blog is for people with cancer, their families, and their friends.  For many people with cancer, today’s treatments are imperfect or even have substantial shortcomings.  Clinical trials may offer something new or different, but unless your regular bedtime reading includes the New England Journal of Medicine or the Journal of Clinical Oncology, the world of clinical trials can seem remote, mysterious, and even inaccessible.  Together, we can change that.  We invite you to join this community and hope you will both learn about clinical trials and teach us by sharing your perspective, experiences, and questions.  Welcome!

Tom and Larry